PTC THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PTC THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $264.73M | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $194.39M | Mar 1, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.73B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $806.78M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $937.82M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $698.80M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $538.59M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $380.77M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $306.98M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $264.73M | Feb 25, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $194.39M | Mar 6, 2018 |
| FY2017 | Dec 31, 2016 | $82.71M | Mar 6, 2018 |
| FY2017 | Dec 31, 2015 | $36.77M | Mar 6, 2018 |
| FY2016 | Dec 31, 2014 | $25.25M | Mar 16, 2017 |
| FY2013 | Dec 31, 2013 | $4.41M | Mar 6, 2014 |
| FY2013 | Sep 30, 2013 | $16.29M | Mar 6, 2014 |
| FY2013 | Jun 30, 2013 | $6.85M | Mar 6, 2014 |
| FY2013 | Mar 31, 2013 | $7.14M | Mar 6, 2014 |
| FY2013 | Dec 31, 2012 | $6.64M | Mar 6, 2014 |
| FY2013 | Sep 30, 2012 | $7.20M | Mar 6, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $682.64M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($363.30M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($626.60M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($559.02M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($523.90M) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | ($74.35M) | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | ($69.69M) | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | ($181.43M) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($112.69M) | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | ($77.68M) | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $866.94M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($302.57M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($439.50M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($447.41M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($374.44M) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | ($96.37M) | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | ($55.13M) | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | ($187.27M) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($92.99M) | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | ($72.78M) | Feb 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $455.25M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $534.48M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $666.56M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $651.50M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $540.68M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $477.64M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $257.45M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $171.98M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $117.46M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $117.63M | Mar 1, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $347.14M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $300.91M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $332.54M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $326.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $285.77M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $245.16M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $202.54M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $153.55M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $121.27M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $97.13M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $711.20M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($107.69M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($158.42M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($356.65M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($251.33M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($194.07M) | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | ($98.64M) | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | ($27.64M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($10.06M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($103.57M) | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.86M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $6.50M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $28.44M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $32.02M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $28.21M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $17.84M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $13.76M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $7.10M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $3.10M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $1.78M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.90B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.71B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.90B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.71B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.94B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $2.21B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.62B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.12B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $391.65M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $269.35M | Mar 6, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.10B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.80B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.71B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.05B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.94B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $1.73B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.03B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $768.50M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $235.22M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $149.76M | Mar 6, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($205.31M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($1.10B) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($818.56M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2022 | ($347.09M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2021 | $1.44M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $481.98M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $594.33M | Feb 21, 2023 |
| FY2021 | Dec 31, 2018 | $350.73M | Feb 22, 2022 |
| FY2020 | Dec 31, 2017 | $156.44M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $119.58M | Mar 2, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.34M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $82.34M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $82.34M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $82.34M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $82.34M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $82.34M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $82.34M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $82.34M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.96B) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($3.65B) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($3.28B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($2.66B) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($2.10B) | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | ($1.63B) | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | ($1.19B) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($938.92M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | ($814.11M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($735.11M) | Mar 6, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $984.65M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $779.71M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $594.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $279.83M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $189.72M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $208.81M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $288.03M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $169.50M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $111.79M | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $58.32M | Mar 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | (8) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | (7) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (7) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (6) | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | (4) | Feb 22, 2022 |
| FY2019 | Dec 31, 2018 | (2) | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | (2) | Mar 2, 2020 |
| FY2014 | Dec 31, 2014 | 0 | Mar 2, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | (8) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | (7) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (7) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (6) | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | (4) | Feb 22, 2022 |
| FY2014 | Dec 31, 2014 | 0 | Mar 2, 2015 |
| FY2014 | Sep 30, 2014 | 0 | Mar 2, 2015 |
| FY2014 | Jun 30, 2014 | 0 | Mar 2, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 81.47M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 77.70M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 75.71M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 73.10M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 70.83M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | 69.72M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | 61.94M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 50.61M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 41.61M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 34.17M | Mar 6, 2018 |